– USA, TX – Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization, announced the appointment of Michael Coyle to its Board of Directors.
Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.
Michael Coyle most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Before that, he was EVP and group president of Medtronic’s cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career.
Michael Coyle is a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies, Inc., and Volcano Corporation.
He earned a master’s degree in business administration from the Wharton School of Business, University of Pennsylvania, and a bachelor’s degree from Case Western Reserve University. He additionally holds six U.S. patents related to cardiovascular medical device products and technologies.
About Integer
Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company’s brands include Greatbatch Medical and Lake Region Medical.
For more information: https://www.integer.net/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.